Biological response genes after single dose administration of interferon beta-1b to healthy male volunteers.

Treatment with interferon beta-1b (IFNB-1b) is clinically effective in multiple sclerosis patients. However, the mechanism of action is only partially understood, and validated biological response markers are lacking. We assessed IFNB-1b-induced transcriptional changes by microarray technology. Healthy male volunteers received 250 mug IFNB-1b or placebo in a double-blind, randomized controlled trial (n=5 per group). Most transcripts demonstrated peak levels after 6-12 h and returned to baseline after 48 h. We identified 227 differentially regulated genes including novel and previously described markers. This panel may become a valuable tool for development of new IFNB-1b formulations and assessment of clinical drug effects.
AuthorsJan Hilpert, Johanna M Beekman, Susanne Schwenke, Kristin Kowal, David Bauer, Johannes Lampe, Rupert Sandbrink, Jürgen F Heubach, Steffen Stürzebecher, Joachim Reischl
JournalJournal of neuroimmunology (J Neuroimmunol) Vol. 199 Issue 1-2 Pg. 115-25 (Aug 13 2008) ISSN: 0165-5728 [Print] Netherlands
PMID18565596 (Publication Type: Journal Article, Randomized Controlled Trial)
Chemical References
  • Adjuvants, Immunologic
  • Immunologic Factors
  • Interferon beta-1b
  • Interferon-beta
  • Adjuvants, Immunologic (pharmacology)
  • Adult
  • Double-Blind Method
  • Gene Expression (drug effects)
  • Gene Expression Profiling
  • Humans
  • Immunologic Factors (genetics)
  • Interferon beta-1b
  • Interferon-beta (pharmacology)
  • Male
  • Oligonucleotide Array Sequence Analysis
  • Principal Component Analysis
  • Reverse Transcriptase Polymerase Chain Reaction

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: